NasdaqGM - Delayed Quote USD

Keen Vision Acquisition Corporation (KVACU)

11.03

-0.06

(-0.54%)

At close: January 16 at 4:00:00 PM EST

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human "Heart-in-a-Jar" to assess cardiac pump performance with Curi Bio’s cloud-based Pulse™ analytics, enabling smart and accelerated cardiac drug screening.Industry-First Capabilities Combined: Medera’s Novoheart has a unique human-based mini-Heart technology platform for disease modelling and drug screening with a track record of supporting FDA IND and FTD applications. As a pi

GlobeNewswire last month

KVAC
+0.09%
KVACU
-0.54%
KVACW
Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapiesFeatures improved automation, environmental control, and flexible testing protocols, setting a new benchmark for human-based cardiac screeningLatest enhanced 96-well technology enables rapid, high-throughput screening on bioengineered human heart tissues, with significant cost and efficiency gains BOSTON and GOTHENBURG, Sweden, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera

GlobeNewswire last month

KVAC
+0.09%
KVACU
-0.54%
KVACW
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Inc. ("Medera"), a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches, announced today the publication of a new study in the peer-reviewed journal Pharmacological Research (volume 209). This study, entitled "Enhanced Drug Classification Using Machine Learning with Multiplexed Cardiac Contractility Assays," demonstrates how Novoheart, Medera's wholly-owned preclinical subsidia

PR Newswire 2 months ago

KVAC
+0.09%
KVACU
-0.54%
KVACW
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. today announced that its clinical-stage gene therapy subsidiary, Sardocor Corp., has successfully completed its Cohort A (low-dose). Following the recommendation of the Data Safety Monitoring Board (DSMB), dosing has begun for patients in Cohort B (high-dose). This Phase 1/2a clinical trial evaluates the first-in-human cardiac gene therapy candidate SRD-002 for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF).

PR Newswire 2 months ago

KVAC
+0.09%
KVACU
-0.54%
KVACW
Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp.

By Karen Roman Biotechnology company Medera Inc. said it entered a definitive merger agreement with Keen Vision Acquisition Corp. (Nasdaq: KVAC), with the combined company having an implied initial enterprise value of approximately $622.6 million. The transaction will close in the fourth quarter and the combined company will be called Medera Inc., both firms said […]

Exec Edge 4 months ago

KVAC
+0.09%
KVACU
-0.54%
KVACW
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Keen Vision Acquisition Corporation ("KVAC") (Nasdaq: KVAC, KVACW) and Medera Inc., ("Medera"), a clinical-stage biotechnology company, announced today that they have entered into a definitive merger agreement. Upon closing of the merger, which is expected to occur in the fourth quarter of 2024, the combined company is to be named Medera Inc.

PR Newswire 4 months ago

KVAC
+0.09%
KVACU
-0.54%
KVACW
With 61% ownership, Keen Vision Acquisition Corporation (NASDAQ:KVAC) boasts of strong institutional backing

Key Insights Given the large stake in the stock by institutions, Keen Vision Acquisition's stock price might be...

Simply Wall St. 6 months ago

KVAC
+0.09%
KVACU
-0.54%
KVACW
Keen Vision Acquisition Corporation (NASDAQ:KVAC) most popular amongst retail investors who own 45% of the shares, institutions hold 32%

Key Insights Keen Vision Acquisition's significant retail investors ownership suggests that the key decisions are...

Simply Wall St. 11 months ago

KVAC
+0.09%
KVACU
-0.54%
KVACW

Performance Overview

Return	KVACU	S&P 500
YTD	+0.36%	+3.04%
1-Year	+6.19%	+25.76%
3-Year	+9.21%	+38.39%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Keen Vision Acquisition Corporation (KVACU)

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp.

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

With 61% ownership, Keen Vision Acquisition Corporation (NASDAQ:KVAC) boasts of strong institutional backing

Keen Vision Acquisition Corporation (NASDAQ:KVAC) most popular amongst retail investors who own 45% of the shares, institutions hold 32%

Performance Overview